Characterization of endothelin-1 receptor subtypes in isolated human cardiomyocytes

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 3, 1999, Pages 333-339

  Modesti, Pietro Amedeo ^a   Vanni, Simone ^a   Paniccia, Rita ^a   Bandinelli, Brunella ^a   Bertolozzi, Iacopo ^a   Polidori, Gianluca ^a   Sani, Guido ^b   Neri Serneri, Gian Gastone ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Endothelin; Growth factors; Myocyte; Receptor antagonists; Receptors

Indexed keywords

5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; GROWTH FACTOR; RECEPTOR SUBTYPE;

ARTICLE; CELL ISOLATION; COMPETITIVE INHIBITION; ENDOTHELIUM CELL; FIBROBLAST; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR UPREGULATION; SECOND MESSENGER;

ANTIHYPERTENSIVE AGENTS; BINDING, COMPETITIVE; CELL MEMBRANE; DANSYL COMPOUNDS; GROWTH SUBSTANCES; HUMANS; IN SITU HYBRIDIZATION; KINETICS; MYOCARDIUM; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN;

EID: 0032816417     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199909000-00003     Document Type: Article

References (44)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;3:411-5.
2. Kitayoschi T, Watanabe T, Shimamoto N. Cardiovascular effects of endothelin in dogs: positive inotropic action in vivo. Eur J Pharmacol 1989;166:519-22.
3. Jones L, Rozick J, Tsutsui H, Cooper G IV. Endothelin stimulates multiple responses in isolated ventricular cardiac myocytes. Am J Physiol 1992;263:H1447-54.
4. 2+ and contractility in singular ventricular myocytes from the ferret and human. Eur J Pharmacol 1992;214:293-6.
5. Giaid A, Saleh D, Yanagisawa M, Clarke Forbes RD. Endothelin immunoreactivity and mRNA in the transplanted human heart. Transplantation 1995;59:1308-13.
6. Plumpton C, Ashby MJ, Kuc RE, O'Reilly G, Davenport AP. Expression of endothelin peptides and mRNA in the human heart. Clin Sci 1996;90:37-16.
7. Ito H, Hirata Y, Miroe M, et al. ET-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991;69:209-15.
8. Takuwa N, TaKuwa Y, Yanagisawa M, Yamashita K, Masaki T. A novel vasoactive peptide stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblast. J Biol Chem 1989;264: 7856-61.
9. Arai M, Yoguchi A, Iso T, et al. Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am J Physiol 1995;268:H2084-91.
10. Yamazaki T, Komuro I, Kudoh S, et al. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 1996;271:3221-8.
11. Hosoda K, Nakao K, Hiroshi-Arai, et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991;287:23-6.
12. Molenaar P, O'Reilly G, Sharkey A, et al. Characterization and localisation of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 1993;72: 526-38.
13. Fareh J, Toujz RM, Shiffrin EL, Thibault G. Endothelin 1 and angiotensin II receptors in cells from rat hypertrophied heart. Circ Res 1996;78:302-11.
14. Thomas PB, Liu ECK, Webb ML, Mukherjee R, Spinale FG. Evidence of the endothelin-1 autocrine loop in cardiac myocytes: relation to contractile function with congestive heart failure. Am J Physiol 1996;40:H2629-73.
15. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. J Pharmacol Exp Ther 1994;46:325-415.
16. Moreland S. Endothelin receptor antagonists: a brief review. Can J Physiol Pharmacol 1994;72:1469-71.
17. Ohlstein EH, Elliott JD, Feuerstein GZ, Ruffolo RR Jr. Endothelin receptors: receptor classification, novel receptor antagonists, and potential therapeutic targets. Med Res Rev 1996;16:365-90.
18. Yazaki Y, Yamazaki T. Reversing congestive heart failure with endothelin receptor antagonists. Circulation 1997;95:1752-4.
19. A antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalene sulfonamide. J Med Chem 1994;37:329-31.
20. Thabes JS, Lefferts PL, Lu WX, Snaffer JR. An endothelin-A receptor antagonist (BMS-182874) attenuates endotoxin-induced lung dysfunction in chronically instrumented awake sheep. Am J Respir Crit Care Med 1994;149:A470.
21. A receptor antagonist. J Pharmacol Exp Ther 1995;272:1124-34.
22. B receptors. Br J Pharmacol 1994;112:1251-7.
23. Peter MG, Davenport AP. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ-788, 50235, Ro462005 and bosentan in the heart. Br J Pharmacol 1996;117:455-62.
24. Reynolds EE, Hwang O, Flynn MA, et al. Pharmacological differences between rat and human endothelin B receptors. Biochem Biophys Res Commun 1995;209:506-12.
25. B receptors in rats. Biochem Biophys Res Commun 1994;199:1461-5.
26. Wang QD, Li XS, Lundberg JM, Pernow J. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res 1995;29:805-12.
27. B receptors in local clearance of endothelin-1 in rat heart: studies with the antagonists PD 155080 and BQ-788. FEBS Lett 1996;396:238-12.
28. Bradford AM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
29. Weiland GA, Molinoff PB. Quantitative analysis of drug-receptor interactions: determination of kinetic and equilibrium properties. Life Sci 1981;29:313-30.
30. Scatchard G. The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 1949;51:660-72.
31. 50) of an enzyme reaction. Biochem Pharmacol 1973;22:3099-109.
32. Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980;107:220-39.
33. Modesti PA, Cecioni I, Migliorini A, et al. Increased renal formation is associated with sodium retention and increased free water clearance. Am J Physiol 1998;275:H1070-7.
34. Elshourbagy NA, Korman DR, Wu HL, et al. Molecular characterization and regulation of human endothelin receptors. J Biol Chem 1993;268:3873-9.
35. B selective ligands in human and rat heart. Br J Pharmacol 1996; 119:631-6.
36. Adachi M, Yang YY, Furuichi Y, Miyamoto C. Cloning and characterization of cDNA encoding human A-type endothelin receptor. Biochem Biophys Res Commun 1991;180:1265-72.
37. Ogawa Y, Nakao K, Arai H, et al. Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 1991;178:248-55.
38. Lee JA, Elliott JD, Sutiphong JA, et al. Tyr-129 is important to the peptide ligand affinity and selectivity of human endothelin type A receptor. Proc Natl Acad Sci USA 1994;91:7164-8.
39. Lee JA, Brinkmann JA, Longton ED, et al. Lysine 182 of endothelin B receptor modulates agonist selectivity and antagonist affinity: evidence for the overlap of peptide and non-peptide ligand binding sites. Biochemistry 1994;33:14543-9.
40. B receptor subtype-selective ligand binding while abolishing phospholipase C activation in both receptors. FEBS Lett 1995;361:243-9.
41. A receptor binding cavity. Biochemistry 1996;35:2548-56.
42. Cowburn PJ, Clealand JGF, Mc Donagh TA, et al. Endothelin clearance in patients with chronic heart failure: implications for anti-endothelin therapy. Circulation 1998;98(suppl I):3A.
43. B receptors: reflects differential receptor phosphorylation. Biochemistry 1997;36: 13325-32.
44. Ponicke K, Volgelsang M, Heinroth M, et al. Endothelin receptors in the failing and nonfailing human heart. Circulation 1998;97: 744-51.